Background: Access to highly active antiretroviral therapy (HAART) is expanding in Latin America (LAC). The aim of this study was to identify factors associated with failure of initial HAART. Methodology: Antiretroviral-naive adults who started their first HAART on or after January 1, 2000 at participating CCASAnet sites were included. Cumulative incidence of virologic failure and major regimen change was estimated considering death as a competing event. Hazard ratios (HR) were computed using univariate and multivariable Cox models. Secondary models with major regimen change as the outcome included Haiti (excluded from the primary analysis due to lack of viral load [VL] data). Results: 13,954 HAART initiators met inclusion criteria (867 from Argentina, 1817 from Brazil, 1075 from Chile, 6468 from Haiti, 917 from Honduras, 811 from Mexico, and 1999 from Peru). Median follow-up was 3.7 years (interquartile range [IQR] 1.8 to 5.9). Nearly 60% of patients were male; the median age at HAART initiation was 37 years (IQR 30 to 44); median CD4 count was 152 cells/mm3 (IQR 60 to 249), and median VLwas 5 log10 copies (IQR 4.5 to 5.4 log10); 39% with AIDS (ranging from 8% in Argentina to 58% in Mexico); median frequency of VL measurement was 3.1 per year; 26% of patients from Honduras did not have VL available; this proportion was less than 2% for the other sitesMost patients at all sites started an NNRTI-based regimen. The cumulative incidence of virologic failure was 9.5%, 18.8% and 27.2% at 1, 3 and 5 years after HAART initiation, respectively. The cumulative incidence of a major regimen change across all sites including Haiti was 2.4%, 7.9% and 13.8% at 1, 3 and 5 years after HAART initiation, respectively. Virologic failure was associated with younger age (adjusted hazard ratio [aHR]= 1.94 for 20 vs. 40 years; 95% CI 1.61-2.34; p<0.001); prior AIDS (aHR=1.31; 95% CI 1.16-1.47; p<0.001); HAART start in earlier calendar years (aHR 1.34 for 2002 vs. 2006; 95% CI 1.21-1.50; p<0.001); non-NNRTIbased regimen (PI-base regimen aHR=1.29; other regimen aHR=1.47; p<0.001). Similarly, younger age and AIDS were both associated with a major regimen change. In contrast, earlier year of first HAART was associated with a decreased risk of regimen change (aHR=0.80 for 2002 vs. 2006). Predictors of major regimen change were similar between Haiti and the Latin American sites. Conclusions: This is the first study to evaluate rates of virologic failure and major regimen change throughout Latin America. Rates were moderate/high, but similar to those seen in North America and Europe. Trends along time may reflect availability of second line drugs. Failure was more likely among younger patients, suggesting the need to design specific strategies for these patients. Partiallly funded by NIH 2-U01-AI069923-06